2-(4-Methoxyphenyl)-3,4,5,6-tetrahydro-1H-azepino[5,4,3-cd]indol-6-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 2-(4-Methoxyphenyl)-3,4,5,6-tetrahydro-1H-azepino[5,4,3-cd]indol-6-one
• 英文别名: 2-(4-Methoxy-phenyl)-1,3,4,5-tetrahydro-azepino[5,4,3-cd]indol-6-one；2-(4-methoxyphenyl)-3,10-diazatricyclo[6.4.1.04,13]trideca-1,4,6,8(13)-tetraen-9-one
• 化学式: C₁₈H₁₆N₂O₂
• 分子量: 292.337
• InChiKey: ALIYTAWXHHSPGS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  54.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  3,4,5,6-tetrahydro-1H-azepino<5,4,3-cd>indol-6-one 在 三苯基膦钯 sodium carbonate 、 lithium chloride 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 、 水 、 甲苯 为溶剂， 生成 2-(4-Methoxyphenyl)-3,4,5,6-tetrahydro-1H-azepino[5,4,3-cd]indol-6-one
  参考文献：
  名称：

  Tricyclic inhibitors of poly(ADP-ribose) polymerases

  摘要：

  以下公式化合物是聚(ADP核糖基)转移酶（PARP）抑制剂，可用于治疗癌症并改善中风、头部创伤和神经退行性疾病的影响。作为癌症治疗药物，本发明的化合物可与细胞毒性药物和/或放射线结合使用。

  公开号：

  US06495541B1

文献信息

• [EN] TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASES<br/>[FR] INHIBITEURS TRICYCLIQUES DE POLY(ADP-RIBOSE) POLYMERASES
  申请人：AGOURON PHARMA

  公开号：WO2000042040A1

  公开（公告）日：2000-07-20

  Compounds of formula (I) are poly(ADP-ribosyl)transferase (PARP) inhibitors, and are useful as therapeutics in treatment of cancers and the amelioration of the effects of stroke, head trauma, and neurodegenerative disease. As cancer therapeutics, the compounds of the invention may be used, e.g., in combination with cytotoxic agents and/or radiation.

  公式（I）的化合物是聚(ADP-核糖基)转移酶（PARP）抑制剂，并可用于治疗癌症和改善中风、头部创伤和神经退行性疾病的影响，作为治疗剂。作为癌症治疗剂，本发明的化合物可以与细胞毒性剂和/或放射线结合使用。
• Novel Tricyclic Poly(ADP-ribose) Polymerase-1 Inhibitors with Potent Anticancer Chemopotentiating Activity:  Design, Synthesis, and X-ray Cocrystal Structure
  作者：Stacie S. Canan Koch、Lars H. Thoresen、Jayashree G. Tikhe、Karen A. Maegley、Robert J. Almassy、Jianke Li、Xiao-Hong Yu、Scott E. Zook、Robert A. Kumpf、Cathy Zhang、Theodore J. Boritzki、Rena N. Mansour、Kanyin E. Zhang、Anne Ekker、Chris R. Calabrese、Nicola J. Curtin、Suzanne Kyle、Huw D. Thomas、Lan-Zhen Wang、A. Hilary Calvert、Bernard T. Golding、Roger J. Griffin、David R. Newell、Stephen E. Webber、Zdenek Hostomsky

  DOI：10.1021/jm020259n

  日期：2002.11.1

  A series of novel compounds have been designed that are potent inhibitors of poly(ADP-ribose) polymerase-1 (PARP-1), and the activity and physical properties have been characterized. The new structural classes, 3,4,5,6-tetrahydro-1H-azepino[5,4,3-cd]indol-6-ones and 3,4-dihydropyrrolo[4,3,2-de]isoquinolin-5-(1H)-ones, have conformationally locked benzamide cores that specifically interact with the PARP-1 protein. The compounds have been evaluated with in vitro cellular assays that measure the ability of the PARP-1 inhibitors to enhance the effect of cytotoxic agents against cancer cell lines.
• TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASES
  申请人：AGOURON PHARMACEUTICALS, INC.

  公开号：EP1140936B1

  公开（公告）日：2004-03-17
• Pharmaceutical Compositions and Method for Treating, Reducing, Ameliorating, Alleviating, or Preventing Dry Eye
  申请人：Zhang Jinzhong

  公开号：US20080305994A1

  公开（公告）日：2008-12-11

  A composition for treating, reducing, ameliorating, alleviating, or preventing a dry eye condition or an opthalmologic disorder that has an etiology in inflammation comprises an inhibitor of activity of poly(ADP-ribose) polymerase (“PARP”). The composition can also include a modulator of pro-inflammatory gene expression.
• US6495541B1
  申请人：——

  公开号：US6495541B1

  公开（公告）日：2002-12-17